Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
The production-linked incentive schemes seek to reimagine the dreams of the Indian economy. It will, of course, take a few years to completely evaluate the impact of them.
Bharat Biotech, founded by Krishna Ella and his wife Suchitra, has been at the forefront of making vaccines for a while. Yet it took a global pandemic for the spotlight to shine on the company.
India’s pharma industry is reimagining itself. This is not just borne out of the necessities brought forth by the pandemic, but is a blueprint to thrive and to succeed in this new world.
The veteran of the investment industry argues that this decade will witness an export-led growth. And while IT and pharma would rule the economy, other smaller industries, too, will jostle to rise up.
Billionaire industrialist Ajay Piramal is in makeover mode. He wants to remould his conglomerate into a well-diversified NBFC and a pharma firm, which would both be giants in their respective spaces.
After a long time, the Union Budget has brought back a renewed focus on healthcare and health infrastructure, which it aims to achieve through a slew of measures. The health industry is elated.
As we look ahead to immunisation in 2021, there is the fear of adverse reactions to the drugs as the vaccines have been tested for less than six months. But a framework exists to deal with such cases.
